Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients

Yuh Sakata, Atsushi Ohtsu, N Horikoshi et al. · European Journal of Cancer · 1998 · 564 citations

Medicine, Oncology, Pharmacology +11

Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer

Wasaburo Koizumi, Minoru Kurihara, Shuji Nakano et al. · Oncology · 2000 · 440 citations

Medicine, Oncology, Pharmacology +15

Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

Tetsuhiko Shirasaka, K Nakano, T Takechi et al. · PubMed · 1996 · 370 citations

Medicine, Oncology, Pharmacology +9

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.

Kunihiko Tatsumi, Masakazu Fukushima, Tetsuhiko Shirasaka et al. · PubMed · 1987 · 261 citations

Life Sciences, Biochemistry, Pharmacology +10

Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.

Keiji Hirata, N Horikoshi, K Aiba et al. · PubMed · 1999 · 227 citations

Pharmacy, Pharmacokinetics, Pharmacology +17